» Articles » PMID: 17485711

Surgical Complications Associated with Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared with SLND Alone in the American College of Surgeons Oncology Group Trial Z0011

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2007 May 9
PMID 17485711
Citations 275
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The American College of Surgeons Oncology Group trial Z0011 was a prospective, randomized, multicenter trial comparing overall survival between patients with positive sentinel lymph nodes (SLNs) who did and did not undergo axillary lymph node dissection (ALND). The current study compares complications associated with SLN dissection (SLND) plus ALND, versus SLND alone.

Patients And Methods: From May 1999 to December 2004, 891 patients were randomly assigned to SLND + ALND (n = 445) or SLND alone (n = 446). Information on wound infection, axillary seroma, paresthesia, brachial plexus injury (BPI), and lymphedema was available for 821 patients.

Results: Adverse surgical effects were reported in 70% (278 of 399) of patients after SLND + ALND and 25% (103 of 411) after SLND alone (P <or= .001). Patients in the SLND + ALND group had more wound infections (P <or= .0016), seromas (P <or= .0001), and paresthesias (P <or= .0001) than those in the SLND-alone group. At 1 year, lymphedema was reported subjectively by 13% (37 of 288) of patients after SLND + ALND and 2% (six of 268) after SLND alone (P <or= .0001). The difference between the two groups' lymphedema, assessed by arm measurements at 30 days (P = .36), 6 months (P = .22), and 1 year (P = .078), although close to the cutoff for significance at 1 year, was not significant. BPIs occurred in less than 1% of patients.

Conclusion: In trial Z0011, the use of SLND + ALND resulted in more wound infections, axillary seromas, and paresthesias than SLND alone. Lymphedema was more common after SLND + ALND but was significantly different only by subjective report. The use of SLND alone resulted in fewer complications.

Citing Articles

Predicting sentinel lymph node metastasis in breast cancer: a study based on the SEER database.

Li Q, Xu H, Bao B, Xie Y, Guo S, Gao Z Clin Exp Med. 2025; 25(1):82.

PMID: 40080204 PMC: 11906503. DOI: 10.1007/s10238-025-01591-5.


Axillary lymph node metastasis in breast cancer: from historical axillary surgery to updated advances in the preoperative diagnosis and axillary management.

Wu T, Long Q, Zeng L, Zhu J, Gao H, Deng Y BMC Surg. 2025; 25(1):81.

PMID: 40016717 PMC: 11869450. DOI: 10.1186/s12893-025-02802-2.


Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol.

van Hemert A, van Loevezijn A, Baas M, Stokkel M, Groen E, van der Noort V Breast. 2025; 80:104411.

PMID: 39954569 PMC: 11872389. DOI: 10.1016/j.breast.2025.104411.


Delta dual‑region DCE-MRI radiomics from breast masses predicts axillary lymph node response after neoadjuvant therapy for breast cancer.

Zeng Q, Deng Y, Nan J, Zou Z, Yu T, Liu L BMC Cancer. 2025; 25(1):264.

PMID: 39953506 PMC: 11827315. DOI: 10.1186/s12885-025-13678-z.


Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial.

Boughey J, Yu H, Switalla K, Velle L, Lopes A, Wallace A Ann Surg Oncol. 2025; .

PMID: 39946078 DOI: 10.1245/s10434-025-16973-y.